JP2013501807A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013501807A5 JP2013501807A5 JP2012524878A JP2012524878A JP2013501807A5 JP 2013501807 A5 JP2013501807 A5 JP 2013501807A5 JP 2012524878 A JP2012524878 A JP 2012524878A JP 2012524878 A JP2012524878 A JP 2012524878A JP 2013501807 A5 JP2013501807 A5 JP 2013501807A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- domain
- antibody
- composition
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 47
- 239000000427 antigen Substances 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 241000712461 unidentified influenza virus Species 0.000 claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 101710154606 Hemagglutinin Proteins 0.000 claims description 12
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 12
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 12
- 101710176177 Protein A56 Proteins 0.000 claims description 12
- 239000000185 hemagglutinin Substances 0.000 claims description 12
- 239000011159 matrix material Substances 0.000 claims description 12
- 206010022000 influenza Diseases 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 229940031348 multivalent vaccine Drugs 0.000 claims description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 8
- 108090000288 Glycoproteins Proteins 0.000 claims description 8
- 102000003886 Glycoproteins Human genes 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- 230000009385 viral infection Effects 0.000 claims description 8
- 239000012472 biological sample Substances 0.000 claims description 7
- 229940123424 Neuraminidase inhibitor Drugs 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 239000013068 control sample Substances 0.000 claims description 4
- 229940126181 ion channel inhibitor Drugs 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000002911 sialidase inhibitor Substances 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims description 2
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical group C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003805 amantadine Drugs 0.000 claims description 2
- 150000001413 amino acids Chemical group 0.000 claims description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000037797 influenza A Diseases 0.000 claims description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 2
- 229960002194 oseltamivir phosphate Drugs 0.000 claims description 2
- 229960000888 rimantadine Drugs 0.000 claims description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 229960001028 zanamivir Drugs 0.000 claims description 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical group CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims description 2
- 206010022005 Influenza viral infections Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 description 5
- 239000012678 infectious agent Substances 0.000 description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23415409P | 2009-08-14 | 2009-08-14 | |
| US61/234,154 | 2009-08-14 | ||
| PCT/US2010/045346 WO2011019932A2 (en) | 2009-08-14 | 2010-08-12 | Compositions and methods for the therapy and diagnosis of influenza |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015030186A Division JP2015120738A (ja) | 2009-08-14 | 2015-02-19 | インフルエンザの治療および診断のための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013501807A JP2013501807A (ja) | 2013-01-17 |
| JP2013501807A5 true JP2013501807A5 (OSRAM) | 2013-09-19 |
Family
ID=43586846
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012524878A Pending JP2013501807A (ja) | 2009-08-14 | 2010-08-12 | インフルエンザの治療および診断のための組成物および方法 |
| JP2015030186A Pending JP2015120738A (ja) | 2009-08-14 | 2015-02-19 | インフルエンザの治療および診断のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015030186A Pending JP2015120738A (ja) | 2009-08-14 | 2015-02-19 | インフルエンザの治療および診断のための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8974788B2 (OSRAM) |
| EP (1) | EP2464383A4 (OSRAM) |
| JP (2) | JP2013501807A (OSRAM) |
| AU (1) | AU2010282415A1 (OSRAM) |
| CA (1) | CA2771105A1 (OSRAM) |
| TW (1) | TW201117825A (OSRAM) |
| WO (1) | WO2011019932A2 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110033476A1 (en) * | 2007-11-12 | 2011-02-10 | Theraclone Sciences Inc. | Compositions and methods for the therapy and diagnosis of influenza |
| EP2220116B1 (en) * | 2007-11-12 | 2012-09-05 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of influenza |
| JP2014506580A (ja) * | 2011-02-14 | 2014-03-17 | セラクローン サイエンシーズ， インコーポレイテッド | インフルエンザの治療および診断のための組成物および方法 |
| CN103533929A (zh) * | 2011-03-15 | 2014-01-22 | 特罗科隆科学有限公司 | 用于流行性感冒的治疗和诊断的组合物和方法 |
| US9969794B2 (en) * | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| US20140363441A1 (en) * | 2013-04-22 | 2014-12-11 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of influenza |
| US20160304586A1 (en) * | 2013-12-05 | 2016-10-20 | Crucell Holland B.V. | Process for preparing influenza vaccines |
| TWI702229B (zh) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| WO2016176212A1 (en) * | 2015-04-27 | 2016-11-03 | The Trustees Of The University Of Pennsylvania | Engineered human anti-aav antibodies and uses thereof |
| EP3999107A1 (en) * | 2019-07-16 | 2022-05-25 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| TWI867224B (zh) * | 2020-06-08 | 2024-12-21 | 中央研究院 | 重組抗體或片段，以及其用途 |
| WO2022132710A1 (en) * | 2020-12-15 | 2022-06-23 | Vanderbilt University | Human hendra virus and nipah virus antibodies and methods of use therefor |
| JP7693813B2 (ja) | 2021-01-14 | 2025-06-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖワクチン及び使用方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY170607A (en) * | 2006-09-07 | 2019-08-20 | Crucell Holland Bv | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| ES2520026T3 (es) * | 2006-09-18 | 2014-11-11 | The Board Of Trustees Of The University Of Arkansas | Composiciones y métodos para potenciar respuestas inmunitarias |
| EP2220116B1 (en) * | 2007-11-12 | 2012-09-05 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of influenza |
| JP5693460B2 (ja) * | 2008-11-12 | 2015-04-01 | セラクローン サイエンシーズ， インコーポレイテッド | ヒトＭ２ｅペプチド免疫原 |
| US8080244B2 (en) * | 2008-11-21 | 2011-12-20 | Los Alamos National Security, Llc | Anti-influenza M2e antibody |
-
2010
- 2010-08-12 EP EP10808769A patent/EP2464383A4/en not_active Withdrawn
- 2010-08-12 CA CA2771105A patent/CA2771105A1/en not_active Abandoned
- 2010-08-12 JP JP2012524878A patent/JP2013501807A/ja active Pending
- 2010-08-12 WO PCT/US2010/045346 patent/WO2011019932A2/en not_active Ceased
- 2010-08-12 AU AU2010282415A patent/AU2010282415A1/en not_active Abandoned
- 2010-08-12 US US12/855,553 patent/US8974788B2/en not_active Expired - Fee Related
- 2010-08-13 TW TW099127135A patent/TW201117825A/zh unknown
-
2015
- 2015-02-19 JP JP2015030186A patent/JP2015120738A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013501807A5 (OSRAM) | ||
| JP2014506580A5 (OSRAM) | ||
| JP6072348B2 (ja) | ２以上のインフルエンザａウイルス中和結合分子を含む組成物 | |
| JP2011501737A5 (OSRAM) | ||
| HRP20201975T1 (hr) | Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba | |
| AU2013259371B2 (en) | Novel HA binding agents | |
| Sun et al. | Seasonal FluMist vaccination induces cross-reactive T cell immunity against H1N1 (2009) influenza and secondary bacterial infections | |
| AU2012326025B2 (en) | Antibodies directed against influenza | |
| Yamayoshi et al. | A broadly reactive human anti-hemagglutinin stem monoclonal antibody that inhibits influenza A virus particle release | |
| US8513391B2 (en) | Monoclonal antibodies for Ebola and Marburg viruses | |
| JP2010521147A5 (OSRAM) | ||
| US11993644B2 (en) | Antigen binding molecules targeting SARS-CoV-2 | |
| JP2011524161A5 (OSRAM) | ||
| EP2793945B1 (en) | Antibodies useful in passive influenza immunization | |
| JP2013531993A5 (OSRAM) | ||
| EA036953B1 (ru) | Человеческие антитела против гемагглютинина вируса гриппа | |
| JP2011528901A5 (OSRAM) | ||
| WO2015131836A1 (zh) | 一种h7型甲型流感病毒的中和抗体及其用途 | |
| JP2015519052A5 (OSRAM) | ||
| JP2016503413A5 (OSRAM) | ||
| JP7372925B2 (ja) | インフルエンザヘマグルチニンに対するヒト抗体 | |
| EP2630242A1 (en) | Identification of antibodies specific for lyssaviruses and methods of their use | |
| US10610587B2 (en) | Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same | |
| JP2014509591A5 (OSRAM) | ||
| WO2014077777A1 (en) | Monoclonal antibodies targeting neutralizing epitopes on h7 influenza viruses |